The once-daily pill Rinvoq, also known as upadacitinib, has a new commercial circulating for 2024. The ad portrays people with moderate to severe eczema attempting to enjoy different pastimes like ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

Rinvoq isn’t the first JAK inhibitor to mount ... where this potential is rapidly becoming a reality. At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole ...

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...

Though it was often joined at the top of the list throughout the year by fellow AbbVie offering Rinvoq, that wasn’t the case in December, when Rinvoq fell two spots as its TV ad spending dropped ...